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Abstract:  Medical imaging is an invaluable tool for diagnosis, surgical 
guidance, and assessment of treatment efficacy. The Network for 
Translational Research (NTR) for Optical Imaging consists of four research 
groups working to “bridge the gap” between lab discovery and clinical use 
of fluorescence-  and photoacoustic-based imaging devices used with 
imaging biomarkers. While the groups are using different modalities, all the 
groups face similar challenges when attempting to validate these systems for 
FDA approval and, ultimately, clinical use. Validation steps taken, as well 
as future needs, are described here. The group hopes to provide translational 
validation guidance for itself, as well as other researchers. 
© 2012 Optical Society of America 
OCIS codes: (170.0110) Imaging systems; (170.3880) Medical and biological imaging. 
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1. Introduction 
Accurate diagnosis, surgical treatment, and assessment of response to treatment all depend on 
the ability to “see” affected tissues and organs. X-ray, CAT (computed axial tomography) 
scan, MRI (molecular resonance imaging), PET (positron emission tomography), and SPECT 
(single-photon emission computed tomography) are imaging technologies currently used in 
clinical practice. With the exception of image-guided invasive biopsy, these imaging 
modalities are not performed at the same time as treatment. Optical imaging, using 
fluorescence, as well as photoacoustic modalities, offers the opportunity for both real-time in 
situ diagnosis and treatment during the same procedure. Even absent therapeutic intervention, 
optical and photoacoustical imaging may be used as real-time imaging modalities, potentially 
affording better resolution, enabling better identification of diseased tissue, and expanding the 
options for obtaining functional and molecular diagnostic information. The Network for 
Translational Research (NTR) for Optical Imaging is a consortium of researchers at several 
medical/academic institutions working to move innovative medical imaging technologies 
from the bench to the clinic. Within the NTR, the Validation/Clinical Studies Core seeks to 
identify and provide guidance for the validation needs of the participating investigators, and in 
so doing, establish best practices for other investigators to use in their efforts to validate the 
combination of medical imaging devices and their companion biomarkers. The need for the 
NTR and the Validation/Clinical Studies Core has arisen due to a shifting landscape of 
product development/approval logistics. Previously, physician or bench scientists would hand 
off inventions to the pharmaceutical industry or device manufacturers for translation into the 
clinic. Now, industry/academic partnerships may be more advantageous, owing to sustained 
interactions between inventors, manufacturers, and end-users. This relationship, however, 
requires new skill sets for academic laboratories in pursuing the validation of their 
technologies. 
Four groups within the NTR are developing different imaging modalities for disease 
detection and diagnosis, as well as surgery guidance and assessment of therapeutic treatment. 
Each group focuses on a particular disease as a model pathological state for the development 
and validation of the imaging system. Three of the four imaging systems include contrast 
agents along with instrumentation. The following brief descriptions of the modalities will 
highlight validation efforts and needs, and Table 1 summarizes their needs. 
2. Optical imaging platforms and validation efforts 
2.1. Photoacoustic tomography (PAT) 
At Washington University in St. Louis, we are utilizing photoacoustic tomography (PAT), 
sometimes referred to as optoacoustic tomography, which is defined as cross-sectional or 
three-dimensional (3D) imaging of a material based on the photoacoustic effect. Therefore, 
PAT possesses spatial resolution along the depth dimension and at least one of the other two 
dimensions. In PAT, light is absorbed by biological tissue and converted to transient heating, 
which is subsequently converted into an ultrasonic wave due to thermoelastic expansion. 
Detection of the ultrasonic wave yields a tomographic image. Combining rich optical contrast  
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Center  Modality  Clinical Applications  Validation Needs 
Washington University at 
St. Louis 
Photoacoustic tomography 
with and without 
biomarkers 
Sentinel lymph node 
imaging and guided needle 
biopsy, early prediction of 
chemotherapy response, 
breast cancer screening 
In vivo studies in 
comparison to existing 
clinical standards 
            The University of Texas 
Health Science Center—
Houston 
Near-infrared fluorescence 
imaging with biomarkers 
Lymphedema treatment 
assessment, non-invasive 
sentinel and cancerous 
lymph node identification, 
surgery guidance 
New probes toxicity and 
batch release, 
cost/effectiveness 
            Stanford University  Visible/near-infrared 
fluorescence imaging with 
biomarkers 
Detection of 
inflammation, 
premalignancies and 
cancer, stratifications of 
tumors for COX-2 
expression 
Demonstration of clinical 
efficacy 
            The University of 
Michigan 
Endoscopic multispectral 
fluorescence imaging with 
biomarkers 
Early detection of 
colorectal cancer using 
specific peptides to target 
flat and depressed lesions 
In vivo peptide specificity 
and toxicity 
and scalable ultrasonic resolution, PAT is the only imaging modality capable of providing 
multiscale, high-resolution structural, functional, and molecular imaging of organelles, cells, 
tissues, and organs in vivo. While functional imaging measures physiological parameters, such 
as oxygenation and blood flow, molecular imaging senses biomarkers to identify specific 
cancer cells or detects gene expression products to track gene activation. 
PAT involves optical excitation, ultrasonic detection, and image formation. A short-pulsed 
laser is usually used to efficiently produce ultrasound in biological tissue. The amplitude of 
the photoacoustic pressure depends on the optical energy deposition, as well as the thermal 
and mechanical properties of the tissue. Because either unscattered or scattered photons can 
produce photoacoustic signals, photoacoustic waves can be generated deep within biological 
tissue. Because the ultrasonic scattering coefficient in tissue is two to three orders of 
magnitude less than the optical counterpart, high spatial resolution can be achieved by 
detecting the photoacoustic waves. Consequently, PAT breaks through the optical diffusion 
limit (~1 mm in the skin) for high-resolution optical-contrast imaging (Fig. 1). The image 
formation is essentially triangulation of the photoacoustic sources according to the time-of-
flight signals recorded at multiple locations. 
Photoacoustic tomography has two major implementations: photoacoustic microscopy 
(PAM) and photoacoustic computed tomography (PACT) [1]. Optical-resolution PAM (OR-
PAM) relies on tightly focused optical excitation to achieve high lateral resolution within the 
optical diffusion limit (~1 mm in tissue). This resolution can be refined to a fraction of an 
optical wavelength or of a micron, as demonstrated in sub-wavelength PAM (SW-PAM) and 
sub-micron PAM (SM-PAM), respectively. Beyond the limit where optical focusing is not 
effective, acoustic-resolution PAM (AR-PAM) takes advantage of the much lower acoustic 
scattering to maintain a high lateral resolution via focused acoustic detection. In contrast to 
focused-scanning PAM, PACT utilizes an ultrasonic array to simultaneously detect the entire 
imaging region. An inverse algorithm is then used to reconstruct a high-resolution image. 
According to the geometry of the array, PACT can be classified into linear-array PACT (LA-
PACT) and circular-array PACT (CA-PACT). 
PAT provides deep imaging at high resolution, and is capable of multiscale imaging (Fig. 
1). To understand the workings of a whole biological system, biological components spanning 
multiple spatial scales—subcellular organelles (sub-µm scale), through cells (µm), to organs 
(cm)—must be integrated. Multiscale PAT with the same contrast mechanism—optical 
absorption—is well positioned for such integration. 
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Fig. 1. (top) Tissue penetration versus resolution for SW-PAM, sub-wavelength photoacoustic 
microscopy; SM-PAM, sub-micron photoacoustic microscopy; OR-PAM, optical-resolution 
photoacoustic microscopy; AR-PAM, acoustic-resolution photoacoustic microscopy; AR-
PAMac, acoustic-resolution photoacoustic macroscopy; and LA-PACT, linear-array 
photoacoustic computed tomography; (bottom) in vivo  multiscale photoacoustic images at 
organelle, cell, tissue, and organ scales. 
PAT is expected to find broad applications in both biology and medicine [2–7]. Preclinical 
applications include imaging of non-fluorescent pigments (red blood cells & melanin), 
angiogenesis and anti-angiogenic response, microcirculation physiology and pathology, drug 
response for screening, brain functions, biomarkers, and gene activities through reporter 
genes. Clinical applications include melanoma cancer screening, gastrointestinal tract 
endoscopy, intravascular catheter imaging, neonatal and adult brain imaging, breast cancer 
detection, prostate cancer detection, guided sentinel lymph node needle/core biopsy for breast 
cancer staging, early response to chemotherapy, dosimetry in thermal therapy, in vivo label-
free histology by photoacoustic imaging of cell nuclei, and blood flow, oxygenation, and 
tissue metabolism imaging. 
Validation of the sensitivity and specificity of PAT is ongoing, and involves comparing in 
vivo  and  ex vivo  imaging of lymph nodes using the contrast dyes methylene blue and 
indocyanine green, and placing exogenous animal tissue over test samples to explore imaging 
depth limits. In the future, the in vivo and ex vivo PAT lymph node imaging will be compared 
to other imaging techniques and histology analysis to validate results. Other validation plans 
include GMP (good manufacturing practice) production of dual-modality imaging agents 
(such as 
125I-methylene blue) and SPECT radionuclide-labeled nanoparticles for correlative 
evaluation of PAT. 
2.2. Near-infrared fluorescence (NIRF) 
In the University of Texas Health Science Center (UTHSC) Center for Molecular Imaging 
(CMI), we are developing near-infrared fluorescence technologies. Currently, the only 
clinically used technologies with sensitivity sufficient for molecular imaging are nuclear 
imaging techniques. Nuclear imaging techniques have significant drawbacks, however, 
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any shelf life, causing difficulties with patient scheduling. In addition, nuclear imaging 
techniques require balancing the half-life of the radiotracer with the pharmacokinetics of the 
targeting agent. The CMI has pioneered a near-infrared fluorescence imaging technique (Fig. 
2), and has developed both imaging agents and instrumentation for sensitive detection of a 
dim fluorophore, indocyanine green (ICG), at femto- to picomolar concentrations in humans 
[8,9]. 
 
Fig. 2. Near-infrared fluorescence imaging of human lymphatics utilizes laser illumination of 
intradermally injected fluorescent dye; (left) fluorophore emissions are captured by an imaging 
system and ICCD (intensified charge-coupled device) camera, producing real-time images and 
movies of lymphatic vessel architecture and function, such as the image (right) of ventral 
forearm lymphatic vessels, yellow scale bar = 5 cm. 
In the United States, there are almost a half million surgical procedures per year for nodal 
staging to determine the number and sites of lymph nodes containing metastatic cancer. 
Lymph node dissection, coupled with radiation treatment, can result in morbidities that 
include lymphedema and diminished response to infections. At the UTHSC, we are working 
to validate the use of our instrumentation to noninvasively detect cancer-positive lymph nodes 
in breast cancer and melanoma patients in order to develop a non-surgical method for nodal 
staging. Initial studies show that the instrumentation can be used with a non-specific dye 
(ICG) to identify draining lymph nodes, compared to currently used (standard-of-care) blue 
dyes. As one form of validation, ex vivo  fluorescent imaging of resected lymph nodes is 
compared to pathology results to determine specificity. In the process of validating the 
sensitivity of our NIRF instrumentation in humans, we unexpectedly visualized the 
“pumping” action of lymphatic vessels draining to lymph nodes and developed the approach 
for assessing lymphatic disorders, including cancer-related lymphedema. This unexpected 
discovery was possible owing to the high photon count rate and fast image acquisition (<200 
milliseconds). Preclinical studies using dual-labeled imaging agents have demonstrated that 
the sensitivity of our instrumentation is comparable to nuclear imaging techniques [10]. 
In addition to our work with ICG, we have conducted safety and toxicity preclinical 
studies of another near-infrared dye, IRDye800CW [11], and we are assessing other 
commercially available near-infrared fluorophores. We are also developing antibody-  and 
peptide-based diagnostic agents to tumor cell targets, such as the epithelial cell adhesion 
molecule (EpCAM), which is expressed in 90% of all cancers [12]. 
Standard validation so  far has included keeping equipment logs for the imaging and 
support instrumentation, frequent updating of Standard Operating Procedures (SOPs), 
personnel training records, and the use and validation of batch release specifications, such as 
optical purity,  immunoreactivity, and pyrogenicity. One published validation paper has 
resulted from these efforts [13], and several more are in preparation. Each time the imaging 
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recorded. This process assures that the laser power is correct, the camera is operating within 
prescribed parameters, and trial information is properly logged by the operator. SciPort is an 
electronic data capture software developed by Siemens Corporate Research, and is being 
adapted to our optical imaging needs by the group. After developing features that make the 
software 21 CFR 11-compliant, the rapid adaptation of good laboratory and clinical practices 
in optical imaging trials could result. 
In addition to agents and instrumentation, we have developed tomographic algorithms for 
detecting fluorescent agents and have adapted a Siemens PET/CT Inveon scanner with near-
infrared technology based upon frequency domain techniques. We are now focusing on 
translating the algorithms in a stepwise fashion after instrumentation and agents are 
introduced into a human exploratory study. All of this work will require validation. The 
technologies that have been translated into the clinic are now being vetted for 
commercialization across the United States. Under NTR support, we have developed the basic 
outline of the 510(k)  for the instrumentation, as well as a CE (European Commission 
harmonized standards) mark for its translation in Europe. 
Currently, the NIRF technology at the UTHSC is the only technology being used to assess 
lymphatic dysfunction in patients who are at risk for lymphedema. This technology has been 
used to demonstrate the efficacy of treatment of lymphedema and wound healing that is 
currently under a decision for national coverage by Medicare/Medicaid. This is a “validation” 
effort to assess treatment efficacy [14]. In addition, this technology is used to phenotype 
subjects for genetic studies to discover the genetic basis for primary and perhaps acquired 
lymphedema. Validation efforts will have to be adapted to new applications that arise from 
such discoveries. 
2.3. Targeted activation of optical imaging probes 
Administration of exogenous molecular probes gives opportunity for specific optical 
activation of these probes where an enzyme is located, hopefully in diseased tissue. At 
Stanford University, we focused on COX-2 (cyclooxygenase-2), which is an attractive target 
for such imaging, because it is not expressed in most normal epithelial cells, but is strongly 
induced in inflammatory, premalignant, and malignant lesions. It is an important contributor 
to the resistance of cancer cells to apoptosis and promotes angiogenesis and metastasis [15]. 
COX-2 inhibitors have demonstrated impressive efficacy in clinical trials for prevention and 
adjuvant therapy [16,17]. Interestingly, COX-2 inhibitors are only efficacious in adjuvant 
therapeutic trials in patients who express COX-2 in their tumors [16]. Thus, COX-2-directed 
imaging agents could find application in early detection, definition of surgical boundaries, and 
patient stratification for targeted therapies. 
The major challenge we faced in developing COX-2-targeted imaging agents was the 
construction of potent and selective inhibitors that also contained optical imaging moieties. 
Previous work from our laboratory indicated that amide derivatives of non-selective 
arylcarboxylic acid COX inhibitors were COX-2-selective, so this was the principal design 
feature we utilized to construct imaging agents [18]. A wide variety of non-steroidal anti-
inflammatory drug cores–e.g., indomethacin, flurbiprofen, ketoprofen, and celecoxib were 
evaluated. These inhibitors were tethered through a series of alkylenes, piperazines, 
polyethylene glycols, or phenylenediamines to a diverse range of fluorophores. The 
fluorophores attached included dansyl, dabsyl, coumarin, fluorescein, rhodamine, Alexa 
Fluor, Nile Blue, Cy5, Cy7, near-infrared and infrared dyes, as well as lanthanide chelators. 
Several hundred conjugates were synthesized and evaluated as inhibitors of COX-2 in 
vitro  and in lipopolysaccharide-treated murine macrophages. Indomethacin conjugates to 
dansyl, dabsyl, coumarin, fluorescein, and rhodamine-derived fluorophores exhibited 
promising COX-2 inhibition and selectivity both in vitro and in intact cells. The compounds 
that emerged from our development pathway, the carboxy-X-rhodamine-containing 
compounds, Fluorocoxib A and Fluorocoxib B (linker = n-butyl), exhibited the best balance of 
cellular activity and optical properties (λex = 581 nm, λemit = 603 nm) [19]. 
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Fig. 3. Fluorocoxib A, a COX-2-targeting peptide (top); and bioluminescent identification of 
dorsal mouse tumor (marked with white arrow in bottom image, with minor liver fluorescence) 
utilizing this COX-2-targeting peptide as the imaging agent. 
A major challenge to molecular imaging of cancer is the validation of candidate 
compounds in intact animals. We devoted at least as much effort to the validation phase as to 
the discovery phase [19], testing the specificity of the compounds in vitro  and  in vivo. 
Fluorocoxibs A and B accumulate in inflamed tissue in COX-2 wild-type mice but not in 
COX-2 knockout mice. Accumulation in wild-type animals is prevented by pretreatment with 
selective or nonselective COX-2 inhibitors. Fluorocoxibs A and B selectively accumulate in 
human tumor xenografts in nude mice if the tumors express COX-2, but not if they do not 
express COX-2 (Fig. 3). Accumulation is slow, requiring up to three hours for maximal 
accumulation, but then displaying a long lifetime in the tumors—up to 24 hours. Fluorocoxibs 
A and B exhibit considerable metabolic stability, which appears to be a key feature of their in 
vivo efficacy. The fluorocoxibs represent the first feasible reagents for clinical detection of 
tissues containing high levels of COX-2 in settings amenable to fluorescent excitation and 
analysis by surface measurement or endoscopy (e.g., skin, esophagus, intestine, and bladder). 
Given the many hurdles that an in vivo  imaging agent must overcome, it is perhaps not 
surprising that our ultimate success rate was approximately one percent, based on the number 
of candidate compounds synthesized. 
The next challenge is advancement of the fluorocoxibs into the clinic. Here the challenges 
are different—e.g., formulation, toxicology, GMP synthesis—and out of the realm of most 
academic laboratories. This is where programs such as the Network for Translational 
Research in Imaging are essential to provide the complementary expertise necessary to move 
molecular imaging agents into human use. Without the NTR, or comparable entities, many 
compounds will be unable to cross the “Valley-of-Death” from promising candidate to useful 
agent, and the exciting potential of molecular imaging of cancer will not be realized. 
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The University of Michigan NTR team is developing a multimodality, multispectral imaging 
platform that uses specific peptides to target overexpressed cell surface receptors in 
premalignant colonic mucosa (dysplasia) [20]. This integrated imaging strategy (Fig. 4) aims 
to improve methods for early detection and image-guided therapy of colorectal cancer, and is 
being developed to address an important unmet clinical need for the improved detection of 
both polypoid and nonpolypoid colonic lesions that may transform into adenocarcinoma [21]. 
The effectiveness of conventional surveillance colonoscopy has been limited by a significant 
miss rate (>20%) for polypoid adenomas, as well as nonpolypoid lesions, with flat or 
depressed morphology, which may represent >25% of all premalignant disease, and may be 
particularly problematic on the right side of the colon. 
 
Fig. 4. Schematic of endoscopic multispectral imaging system (top); and (bottom) fluorescent 
and white light images of highly specific peptide targeting of colonic dysplasia (arrows) using 
(left to right) 440, 532, and 635 nm excitation [26]. 
#160300 - $15.00 USD Received 21 Dec 2011; revised 10 Feb 2012; accepted 13 Feb 2012; published 22 Mar 2012
(C) 2012 OSA 1 April 2012 / Vol. 3,  No. 4 / BIOMEDICAL OPTICS EXPRESS  772Peptides are well suited for clinical detection of dysplasia because of their rapid binding 
kinetics and high specificity. In addition, they are small in size, have flexibility for labeling, 
and incur minimal immunogenicity [22]. Methods of nuclear (scintigraphic) imaging are 
being developed to localize the anatomic segment of the colon where the premalignant 
mucosa may be present by radiolabeling the peptides [23]. Then, wide-field fluorescence 
endoscopy is utilized to perform “red flag” detection of the lesion and to clearly delineate the 
tumor margins for image-guided therapy [24]. Localization of disease allows for placement of 
a confocal endomicrosope to validate specific peptide binding to dysplastic colonic crypts 
with subcellular resolution [25] and for use of an endoscopic ultrasound (EUS) transducer to 
stage the depth of invasion. 
We are partnering with GE Healthcare, Olympus Medical Systems Corp, and Mauna Kea 
Technologies to standardize and validate the use of this comprehensive, targeted imaging 
platform. Olympus is modifying a wide-field autofluorescence imaging (AFI) system to 
deliver narrow-band excitation (440-480 nm) for illuminating the FITC-labeled peptides 
[27,28]. An investigational new drug (IND) application has been approved by the FDA, and a 
Phase 1 study has been completed to evaluate the safety and specificity of these molecular 
probes [29]. 
Challenges for bringing this targeted imaging strategy to the market include 1) addressing 
regulatory requirements for safe and effective use of this novel imaging agent with the new 
instrument, 2) CMS (Centers for Medicare and Medicaid Services) approval for 
reimbursement of this innovative procedure, and 3) acceptance of this method by the medical 
community. This targeted approach will improve current methods of colorectal cancer 
surveillance by identifying lesions that cannot be seen or are missed, increasing the yield for 
detection of dysplasia, and more accurately defining the margin for tumor resection. 
The validation activities are multifaceted and begin with the GMP synthesis and structural 
elucidation of the fluorescent peptides to be used for imaging studies. The peptide molecular 
identification and solution concentrations are also confirmed during analytical validation; 
their safety is established through GLP (good laboratory practices) toxicological studies. 
Further validation efforts include ex vivo histological evaluation. Eventual confirmation of 
safety and efficacy from phase 1 in vivo results will be performed by an independent center. 
A number of additional validation steps are part of our efforts to bring this technology to 
the clinic. For example, we use fully validated release assay test procedures running on 
appropriately qualified analytical instrumentation (UPLC/HPLC/MS [ultraperformance liquid 
chromatography, high-performance liquid chromatography, mass spectrometry]) at the GMP 
facility where the affinity peptides are synthesized to confirm the peptide sequence, amino 
acid analysis, molecular identity, and purity of the drug substance. We also confirm various 
concentrations of the affinity peptide, both in dosing medium and in biological fluids, during 
toxicology studies at a GLP facility using fully validated assay test procedures running on 
appropriately qualified analytical instrumentation (UPLC/HPLC/MS/UV [ultraviolet]). For 
specificity and sensitivity validation, fluorescence stereomicroscopy of imaging ex vivo data is 
compared directly to histology results by accurate registration of pathology sections (<1 mm
2 
resolution) and evaluation by a gastrointestinal pathologist. A final validation step is in the 
planning stages, and will involve the reverification of the data and results from the current 
Phase 1 safety and efficacy study by an independent second research center. 
3. NTR Validation/Clinical Studies core’s role 
The four NTR centers’ imaging technologies, while different, share similar needs for 
translational validation. The NTR Validation/Clinical Studies core (VCS) initially tried to 
accurately and relevantly define these needs. Using a validation self-assessment tool designed 
for individual investigators, the validation needs and progress were determined for each 
network partner. In another, broader survey, the VCS core found that all four centers are at 
slightly different points in the translation process, and use different methods to move along 
the “translation pipeline,” as represented in Fig. 5. For example, some NTR researchers are at 
the 510(k) stage for instrumentation, and at the development stage for markers. Several NTR 
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independently to produce and test an instrument prototype. One research group utilizes a CRO 
(contract research organization) for toxicity studies. Several groups have received IND 
approval, while others have requested help with the IND/IDE (investigational device 
exemption) process. One of the groups began talking to the FDA before the Office of 
Combination Products (OCP), which handles device-drug or device-biologic combinations, 
was established. This NTR group initially completed separate applications for their device and 
agent. Once OCP was established, the OCP instructed this group to apply through CDER 
(drugs only). For the off-label use of the imaging agent (indocyanine green), the group will 
need to apply for an ANDA (abbreviated new drug application), for which no preclinical or 
clinical data are  needed for safety and effectiveness, and the device will use the 501(k) 
process. Three of the four groups are developing instrumentation and related biomarkers, and 
thus need guidance through OCP procedures. 
It is important to distinguish “verification”  from “validation” in the context of 
technological product development. Verification is a quality control process that evaluates if 
an engineering system satisfies its original design specification. For example, the NIRF 
systems pictured in Fig. 2 are verified using a checksheet/SOP prior to each use in clinical 
trials. Laser output, software performance, and image quality are confirmed and documented. 
Validation is a quality assurance process to establish that an imaging system fulfills the needs 
of end users–for example, the system actually images and distinguishes cancerous tissue. 
 
Fig. 5. The translation pipeline and validation needs. Some validation steps are needed 
throughout the translation process, and some steps are only necessary during portions of the 
process. Design iterations are designated by arched arrows. 
In the context of translation, validation exists on several levels, and these levels can be 
difficult to conceptualize. At the most basic level for meeting GLP/GMP/GCP (good clinical 
practices) compliance, routine recordkeeping and use of standard operating procedures (SOPs) 
are essential. A higher level of validation necessitates proving imaging agent purity, sterility, 
immunogenicity, pyrogenicity, stability, or imaging device sterility, pyrogenicity, and 
reliability. The highest level of validation addresses clinical effectiveness of imaging agents or 
devices for diagnosing and treating disease, and may include cost analysis. The 
Validation/Clinical Studies (VCS) Core has identified specific validation guidelines for each 
of the levels. 
The VCS Core recognized a number of validation hurdles. For example, despite several 
publications that have addressed translation of optical imaging devices [30–32], very few 
published validation protocols exist for batch release criteria for imaging devices and 
molecular imaging agents. Also, many researchers do not have CRO skill sets and institutional 
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optical imaging-specific handbook [33], which is a consolidation of appropriate FDA 
guidances and other sources that are most relevant to validation efforts within the NTR 
network. The information in the handbook is tailored to three of the four NTR research 
groups, which are developing combinatorial imaging agents and devices, but most of the 
handbook is applicable to those researchers developing devices without imaging agents. The 
handbook lists useful links and references that support pre-IND/IDE submissions, IND/IDE 
submissions, and guidances and regulations relevant to the NTR, such as a guidance for 
combination products. The VCS Core’s section of the handbook specifically addresses 
validation topics, starting with an abbreviated glossary of terms needed for  mid-level 
validations, and a general procedural outline for designing mid-level and high-level validation 
efforts. 
The VCS Core has attempted to establish concrete validation objectives and outcomes for 
NTR. At the ground-floor level, involving SOPs and other regulatory paperwork, validation 
can be accomplished using a software tool (SciPort) [34] for electronic data entry and 
analysis. Software such as SciPort or other electronic data capture (EDC) systems can and 
should be used for bench and pre-clinical data collection and analysis, as well as SOP access, 
and computers used with bench equipment such as spectrophotometers and plate readers 
should employ 21 CFR Part 11-compliant software to document data entry, assure instrument 
performance, and deter data  falsification.  One paper produced by the UTHSC group has 
addressed a mid-level validation issue [13], and could be used as a guide by other groups. 
Another paper [35] describes the development of a phantom validation approach. The highest 
validation level, addressing effectiveness of imaging agents or devices for diagnosing and 
treating disease, remains to be fully developed by the core. Several papers produced by the 
UT group have assessed outside treatments using a UT medical device [14,36], and have 
compared optical to nuclear imaging using dual-labeling approaches [10]. While dual-labeled 
markers cannot yield perfect comparisons, simultaneous fluorescent and radioactive targeting 
that corresponds to radioactive targeting alone can give important information on the 
usefulness and validity of new fluorescent imaging techniques. Other methods need similar 
attention at this level. For instance, a pathology/histology study could help provide guidelines 
for the investigators. Additionally, cost effectiveness may be addressed, either by the 
investigator, by NTR, or a collaborative effort, perhaps involving CMS. 
4. Future ambitions of the NTR Validation/Clinical Studies core and the NTR centers 
Future goals of the VCS core include several publications that could aid not only NTR 
members, but also other groups and researchers striving to bridge the gap between lab bench 
discoveries and clinical use. A publication describing the real or hypothetical validation or 
quality control for pathology use in optical imaging could set a standard for specificity and 
sensitivity measurement in optical imaging. For instance, a pathology/histology study could 
help provide guidelines for the investigators, noting the need to engage pathologists 
throughout the project timeline [37].  A publication describing a real or hypothetical 
cost/benefit analysis for an optical imaging application would address a new, but most 
relevant, issue concerning CMS approval and reimbursement. Products that do not merit such 
approval have little chance of market success, and therefore, translational investment support. 
Failure of innovative medical devices and agents to “make it” to the marketplace 
represents wasted private and tax dollars, deepens researchers’ frustrations, and discourages 
potential investors from supplying much-needed development capital. Development of tools 
to aid researchers in moving innovations from concepts to lab tests to clinical applications and 
marketable products is vital to continuing the momentum of current medical research. 
Improved medical care, healthier societies, and increased tax dollar revenues are all benefits 
of smooth translation of technologies. Imaging lies at the heart of medical diagnosis and 
treatment, and rapid translation of new optical imaging modalities is of vital importance. The 
NTR Validation/Clinical Studies Core will continue to develop tools for researchers within 
and out of the NTR network to efficiently translate their cutting-edge technologies. 
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